| DIRECT COMPETITOR COMPARISON | |
| MYGN | ABT | HOLX | Pvt1 | Industry | | Market Cap: | 2.30B | 83.65B | 3.71B | N/A | 62.33M | | Employees: | 869 | 72,000 | N/A | N/A | 56 | | Qtrly Rev Growth (yoy): | 21.70% | 3.50% | -9.00% | N/A | 18.90% | | Revenue (ttm): | 341.68M | 29.92B | 1.64B | N/A | 12.73M | | Gross Margin (ttm): | 81.34% | 58.31% | 62.20% | N/A | 50.63% | | EBITDA (ttm): | 141.76M | 8.64B | 600.43M | N/A | -1.76M | | Oper Margins (ttm): | 38.86% | 22.32% | 20.12% | N/A | -19.80% | | Net Income (ttm): | 142.16M | 5.60B | -2.18B | N/A | N/A | | EPS (ttm): | 1.013 | 3.691 | -8.483 | N/A | N/A | | P/E (ttm): | 23.64 | 14.65 | N/A | N/A | 23.64 | | PEG (5 yr expected): | 0.72 | 1.27 | 1.2 | N/A | 1.36 | | P/S (ttm): | 6.79 | 2.81 | 2.31 | N/A | 3.09 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|
1.48% Nasdaq 
Competitors
